{
    "id": 7651,
    "name": "small-cell carcinoma of the ovary of hypercalcemic type",
    "source": "DOID",
    "definition": "An ovarian small cell carcinoma that is associated with paraneoplastic hypercalcemia. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939673/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:7651",
    "evidence": [
        {
            "id": 15945,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) cell lines and xenografts with mutant SMARCA4 resulted in decreased cell viability and tumor volume (PMID: 29440177).",
            "molecularProfile": {
                "id": 22426,
                "profileName": "SMARCA4 mutant"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 7651,
                "name": "small-cell carcinoma of the ovary of hypercalcemic type",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14061,
                    "pubMedId": 29440177,
                    "title": "Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29440177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}